We’ve developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities

Our mission is to transform cancer treatment for patients by developing evorpacept as a first-in-class foundational checkpoint immunotherapy

Evorpacept Mechanism of Action

ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, evorpacept (ALX148), will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue evorpacept as a potentially critical component for future combination treatments in oncology.

Latest News updated at 07:20:26 UTC

Jun 02, 2024

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

May 29, 2024

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 09, 2024

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update


New $ALXO #clinicaldata at #ASCO24: First evorpacept combination data with an ADC from Phase 1 ASPEN-07 clinical trial in patients with advanced bladder cancer. More details here: https://bit.ly/4aKZiy5

See you at @Jefferies Healthcare Conference in NYC next week! Our CEO, @JasonLettmann and Michael Yee will recap accomplished milestones, new clinical data being presented at #ASCO24, and what to expect for the rest of 2024 in a fireside chat. https://bit.ly/4aE2pYz

Today, our CEO @JasonLettmann discussed upcoming catalysts in a fireside chat with research analyst Ramakanth Swayampakula at the H.C. Wainwright Second Annual BioConnect #Investor Conference at Nasdaq. $ALXO Watch here: https://bit.ly/3QTso7r

Load More

Our Technology

ALX Oncology’s fusion proteins are engineered to bind CD47 with significantly greater affinity than natural SIRPα. Our lead candidate, evorpacept, is an intravenously administered fusion protein containing two engineered high affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin.